Altre lingue XOMA Corporation

Azioni

XOMA

US98419J2069

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
25,41 ^USD	+0,20%		-0,27%	+37,35%

03/04	XOMA Corporation (NasdaqGM:XOMA) ha completato l'acquisizione di Kinnate Biopharma Inc. (NasdaqGS:KNTE).	CI
08/03	XOMA Corporation riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	25/04
XOMA : Acquisition/Asset Disposal - Form 8-K	03/04
XOMA Corporation Announces Closing of Tender Offer	03/04
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	03/04
XOMA Declares Quarterly Preferred Stock Dividends	21/03
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	19/03
Xoma: Q4 Earnings Snapshot	08/03
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	08/03
XOMA to Present at Upcoming Investor Conferences in March	28/02
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	19/02
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	16/02
Sector Update: Health Care Stocks Advance Friday Afternoon	16/02
XOMA Agrees to Acquire Kinnate Biopharma	16/02
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right	16/02
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million.	16/02
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition	19/01
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million	18/01
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition	18/01
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.	18/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue XOMA Corporation

Azioni

XOMA

US98419J2069

Altre lingue

Filtri